American Society of Clinical Oncology (ASCO)

Atezolizumab in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC) extends disease-free survival compared with best supportive care after receiving adjuvant chemotherapy. Read More ›

Patients with pretreated KRAS p.G12C–mutated non–small-cell lung cancer (NSCLC) treated with sotorasib improved or maintained global health status/quality of life, physical functioning, and the severity of key lung cancer–related symptoms. Read More ›

Significant racial disparities exist among lung cancer survivors in receipt of surveillance scans, guidance about follow-up care, and smoking cessation. Read More ›

Findings from KEYNOTE-598 detected no difference in health-related quality of life or time to true deterioration in lung cancer symptoms comparing treatment with pembrolizumab + ipilimumab versus pembrolizumab + placebo in patients with previously untreated metastatic non–small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score ≥50%. Read More ›

Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma. Read More ›

Sotorasib, an oral KRAS inhibitor, was effective across specified subgroups of patients with KRAS G12C–mutated non–small-cell lung cancer (NSCLC). Read More ›

The cost burden of adjunctive osimertinib therapy is higher than the observed clinical benefit for patients with resected EGFR-positive non–small-cell lung cancer (NSCLC). Read More ›

The ACCURE intervention using a combination of real-time electronic health record monitoring, nurse navigation, and race-based feedback significantly improved delivery of timely lung cancer surgery and markedly reduced racial disparities for patients with early-stage lung cancer. Read More ›

The combination of EGFR-tyrosine kinase inhibitor (TKI) and MET-TKI therapy improves clinical outcomes in patients who developed MET amplification after prior EGFR-TKI therapy in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›

First-line use of nivolumab + ipilimumab in patients with advanced non–small-cell lung cancer (NSCLC) offers durable survival relative to chemotherapy alone with ≥2 years of follow-up. Read More ›